|
|
|
|
|
|
|
|
|
|
Interpretation of single and serial measures of HE4 and CA125 in asymptomatic women at high risk for ovarian cancer
Abstract
Background.
Human epididymis protein 4
(HE4) is approved for clinical use with CA125 to predict epithelial
ovarian cancer
(EOC) in women with a pelvic mass or in remission
after chemotherapy. Previously reported reference ranges for HE4 are
inconsistent.
Methods.
We report positivity thresholds yielding
90%, 95%, 98% and 99% specificity for age-defined populations of healthy
women for HE4, CA125 and Risk of Malignancy
Algorithm (ROMA), a weighted average of HE4 and CA125. HE4 and CA125
were measured
in 1780 samples from 778 healthy women aged >25
years with a documented deleterious mutation, or aged >35 years with a
significant
family history. Effects on marker levels of a
woman's age, ethnicity and epidemiologic characteristics were estimated,
as
were the population-specific means, variances and
within- and between-woman variances used to generate longitudinal
screening
algorithms for these markers.
Results.
CA125 levels were lower with Black
ethnicity (p=0.008). Smoking was associated with higher HE4 (p=0.007)
and ROMA
(p<0.019). Continuous oral contraceptive use
decreased levels of CA125 (p=0.041), and ROMA (p=0.12). CA125 was lower
in women
age ≥55, and HE4 increased with age (p<0.01),
particularly among women age ≥55.
Conclusions.
Due to the strong effect of age on
HE4, thresholds for HE4 are best defined for women of specific ages.
Age-specific
population thresholds for HE4 for 95% specificity
ranged from 41.4 pmol/L for women age 30 to 82.1 pmol/L for women age
80.
Impact. Incorporation of serial marker values from
screening history reduces personalized thresholds for CA125 and HE4 but
is inappropriate for ROMA.
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.